Knowledge.
Experience.
Results.
Markwell LLP
We are a drug regulatory and patent litigation law firm in Toronto, Canada.
In our regulatory litigation practice, we represent innovative pharmaceutical and biotechnology companies in disputes with the government and private payers relating to the manufacture, use and sale of drug products in Canada, including clinical trials, product approvals, data protection, patent term restoration, patent listings (PMNOC), pricing (PMPRB), health technology assessments, and formulary listings.
Our Lawyers
Jason Markwell
Jason has appeared as counsel in many precedent-setting cases before the Supreme Court of Canada, the Federal Court of Appeal, the Federal Court, the Ontario Superior Court of Justice, and the Patented Medicine Prices Review Board. Jason has been recognized as a leading intellectual property lawyer by Chambers & Partners, IAM Patent 1000, The Best Lawyers Canada, Who’s Who Legal, IP Stars, Martindale Hubbell, Lexpert (consistently recommended in Intellectual Property, Litigation-Intellectual Property, and Life Sciences), Benchmark Litigation (IP Litigator of the Year, 2017), The Lexpert/American Lawyer Guide to the Leading 500 Lawyers in Canada, Managing Intellectual Property (Outstanding IP Practitioner – Canada, 2019), and LMG Life Sciences (Lawyer of the Year, 2018, Patent Litigation). Jason is active in various intellectual property organizations, including the Intellectual Property Institute of Canada (IPIC) and the International Association for the Protection of Intellectual Property (AIPPI Standing committee on Biotechnology).
Rebecca Crane
Rebecca’s Ph.D. dissertation focused on the purification and characterization of osmoregulatory proteins of Escherichia coli. She has significant research experience in biochemistry, molecular biology, and microbiology. Prior to joining Markwell LLP, Rebecca practised at several leading law firms in their patent litigation groups. Rebecca’s legal and scientific background allows her to uniquely understand clients’ technology, business objectives, and product portfolios in support of their patent litigation and regulatory matters. Rebecca frequently represents life sciences and pharmaceutical industry clients in patent litigation matters and strategic product regulatory advice, including on matters related to Canada’s Patented Medicines Prices Review Board (PMPRB). Since 2021, Rebecca has been selected as one of Canada’s best patent professionals in the IAM Patent 1000 rankings.